CDK4 and breast carcinoma: At the clinical level, we verified the roles of LRPPRC in CDK4/6i treatment response by Immunohistochemical (IHC) experiment using samples from breast cancer patients, as breast cancer is the only approved clinical application for CDK4/6i.